425 related articles for article (PubMed ID: 29051030)
1. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
2. Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
Abe H; Takei K; Uematsu T; Tokura Y; Suzuki I; Sakamoto K; Nishihara D; Yamaguchi Y; Mizuno T; Nukui A; Kobayashi M; Kamai T
Int J Clin Oncol; 2018 Apr; 23(2):338-346. PubMed ID: 29098519
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
[TBL] [Abstract][Full Text] [Related]
4. Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Tanabe K
Target Oncol; 2018 Dec; 13(6):745-755. PubMed ID: 30328067
[TBL] [Abstract][Full Text] [Related]
5. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
6. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma.
Fukushima H; Yokoyama M; Nakanishi Y; Tobisu K; Koga F
PLoS One; 2015; 10(1):e0115895. PubMed ID: 25612215
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
10. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
11. Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.
Fukushima H; Nakanishi Y; Kataoka M; Tobisu KI; Koga F
Clin Genitourin Cancer; 2017 Apr; 15(2):e229-e238. PubMed ID: 27601279
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.
Yumioka T; Honda M; Nishikawa R; Teraoka S; Kimura Y; Iwamoto H; Morizane S; Hikita K; Takenaka A
Int J Clin Oncol; 2020 Jan; 25(1):158-164. PubMed ID: 31520176
[TBL] [Abstract][Full Text] [Related]
13. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
14. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.
Cortellini A; Palumbo P; Porzio G; Verna L; Giordano AV; Masciocchi C; Parisi A; Cannita K; Ficorella C; Bozzetti F
Thorac Cancer; 2018 Dec; 9(12):1623-1630. PubMed ID: 30259689
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.
; Mari A; D'Andrea D; Kimura S; Resch I; Shariat SF; Klatte T
Urol Int; 2018; 101(2):197-200. PubMed ID: 30089304
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
[TBL] [Abstract][Full Text] [Related]
18. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Uemura S; Iwashita T; Ichikawa H; Iwasa Y; Mita N; Shiraki M; Shimizu M
Br J Nutr; 2021 May; 125(10):1140-1147. PubMed ID: 32883372
[TBL] [Abstract][Full Text] [Related]
19. Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma.
Taguchi S; Akamatsu N; Nakagawa T; Gonoi W; Kanatani A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Homma Y
Clin Genitourin Cancer; 2016 Jun; 14(3):237-43. PubMed ID: 26337653
[TBL] [Abstract][Full Text] [Related]
20. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
